A Comparative Clinical Evaluation of Tiladi churna and Pootikadi Lepa in the management of Daad(khujli)

A Comparative Clinical Evaluation of Tiladi churna and Pootikadi Lepa in the management of Dadru(Tinea cruris)

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/05/013834

Enrollment

Registered

2018-05-11

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Dadru(Tinea cruris)

Interventions

Intervention1: Tiladi Churna Pootikadi Lepa: Tiladi Churna will be given 5 gm BD for four weeks and Pootikadi Lepa BD for four weeks on affected parts Control Intervention1: Itraconazole 100 mg Terbi

Eligibility

Inclusion criteria

Inclusion criteria: Patient Willing to Participate in Above Mentioned Trial Only Diagnosed Case of Tinea Cruris

Exclusion criteria

Exclusion criteria: Age group less than 16 years and more than 60 years Any sensitivity reaction to the Preparation Skin cancer Psoriasis Eczema etc associated with Fungal infection Diabetic and cardiac patients Pregnant and Lactating women

Design outcomes

Primary

Measure	Time frame
Assessment will be done on the basis of Prepared proforma Changes in Itching Span of Erythmatous plaque Extension of Patches LichenificationTimepoint: Fifteen days One Month	—

Secondary

Measure	Time frame
Not ApplicableTimepoint: Not Applicable	—

Countries

India

Contacts

Public ContactPriyanka Yadav

Institute of Medical Sciences Banaras Hindu University

singhopbhu@gmail.com9415818732

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026